nVerses Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

nVerses Capital’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,422	Closed	-$194K	–	312
2026 Q1	$194K	Buy	+20,422	New	+$159K	0.18%	278
2024 Q4	–	Sell	-15,500	Closed	-$118K	–	103
2024 Q3	$118K	Buy	15,500 +5,300	+52%	+$40.3K	0.05%	443
2024 Q2	$63K	Buy	+10,200	New	+$56.3K	0.04%	551

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

nVerses Capital's BCRX Position: Q2 2026 in Review

nVerses Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 20,422 shares — an estimated $194K sold.

nVerses Capital first reported a position in BCRX in Q2 2024 and held it in 3 quarters. The position peaked at $194K in Q1 2026. 232 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

nVerses Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
nVerses Capital sold 20,422 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $194K.
nVerses Capital first reported a position in BioCryst Pharmaceuticals in Q2 2024 and held it in 3 quarters.
nVerses Capital's BioCryst Pharmaceuticals position peaked at $194K in Q1 2026.
232 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on nVerses Capital's 13F filing for Q2 2026, filed 4 Aug 2026.